| Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant S Sun, CCT Sprenger, RL Vessella, K Haugk, K Soriano, EA Mostaghel, ... The Journal of clinical investigation 120 (8), 2715-2730, 2010 | 873 | 2010 |
| Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling EG Bluemn, IM Coleman, JM Lucas, RT Coleman, S Hernandez-Lopez, ... Cancer cell 32 (4), 474-489. e6, 2017 | 617 | 2017 |
| Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer MP Labrecque, IM Coleman, LG Brown, LD True, L Kollath, B Lakely, ... The Journal of clinical investigation 129 (10), 4492-4505, 2019 | 295 | 2019 |
| LuCaP prostate cancer patient‐derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics HM Nguyen, RL Vessella, C Morrissey, LG Brown, IM Coleman, ... The Prostate 77 (6), 654-671, 2017 | 267 | 2017 |
| Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial O Mosenzon, TM Blicher, S Rosenlund, JW Eriksson, S Heller, OH Hels, ... The lancet Diabetes & endocrinology 7 (7), 515-527, 2019 | 261 | 2019 |
| Prostate cancer reactivates developmental epigenomic programs during metastatic progression MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ... Nature genetics 52 (8), 790-799, 2020 | 193 | 2020 |
| Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer A Ghoochani, EC Hsu, M Aslan, MA Rice, HM Nguyen, JD Brooks, ... Cancer research 81 (6), 1583-1594, 2021 | 188 | 2021 |
| A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening ML Beshiri, CM Tice, C Tran, HM Nguyen, AG Sowalsky, S Agarwal, ... Clinical Cancer Research 24 (17), 4332-4345, 2018 | 180 | 2018 |
| Metastatic progression of prostate cancer and e-cadherin: Regulation by Zeb1 and Src family kinases AP Putzke, AP Ventura, AM Bailey, C Akture, J Opoku-Ansah, M Çeliktaş, ... The American journal of pathology 179 (1), 400-410, 2011 | 168 | 2011 |
| Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer L Fontana, RM Adelaiye, AL Rastelli, KM Miles, E Ciamporcero, ... Oncotarget 4 (12), 2451, 2013 | 149 | 2013 |
| Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis T Koreckij, H Nguyen, LG Brown, EY Yu, RL Vessella, E Corey British journal of cancer 101 (2), 263-268, 2009 | 113 | 2009 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature Communications 12 (1), 1979, 2021 | 95 | 2021 |
| Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models NM Navone, WM van Weerden, RL Vessella, ED Williams, Y Wang, ... The Prostate 78 (16), 1262-1282, 2018 | 91 | 2018 |
| Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer P Cejas, Y Xie, A Font-Tello, K Lim, S Syamala, X Qiu, AK Tewari, N Shah, ... Nature communications 12 (1), 5775, 2021 | 79 | 2021 |
| Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling HM Nguyen, N Ruppender, X Zhang, LG Brown, TS Gross, C Morrissey, ... PloS one 8 (10), e78881, 2013 | 70 | 2013 |
| Effect of castration, DES, flutamide, and the 5α‐reductase inhibitor, MK‐906, on the growth of the dunning rat prostatic carcinoma, R‐3327 JR Brooks, C Berman, H Nguyen, S Prahalada, RL Primka, ... The Prostate 18 (3), 215-227, 1991 | 60 | 1991 |
| Cellular adhesion promotes prostate cancer cells escape from dormancy N Ruppender, S Larson, B Lakely, L Kollath, L Brown, I Coleman, ... PLoS One 10 (6), e0130565, 2015 | 59 | 2015 |
| Durable response of enzalutamide-resistant prostate cancer to supraphysiological testosterone is associated with a multifaceted growth suppression and impaired DNA damage … HM Lam, HM Nguyen, MP Labrecque, LG Brown, IM Coleman, R Gulati, ... European urology 77 (2), 144-155, 2020 | 56 | 2020 |
| Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts VA DiPippo, WC Olson, HM Nguyen, LG Brown, RL Vessella, E Corey The Prostate 75 (3), 303-313, 2015 | 45 | 2015 |
| Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone PS Kirk, T Koreckij, HM Nguyen, LG Brown, LA Snyder, RL Vessella, ... International journal of molecular sciences 14 (5), 10483-10496, 2013 | 45 | 2013 |
